| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Elissa J. Schwartz is Director at GALT. Elissa J. Schwartz's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3K at current prices.
Net of sales, the GALT filings show accumulation of 1,000 shares.
Elissa J. Schwartz has 7 Form 4 filings on record from March 2021 to January 2026, all as Director at Galectin Therapeutics (GALT), 2021–2026.
The 8 reported transactions were 7 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $2K and no sales.
The only open-market purchase was 1,000 shares of GALT at an average $2.00 on January 21, 2022, about $2K. Twelve months later GALT was down 41%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 21, 2022 | GALT Galectin Therapeutics Inc | Director | Buy | 1,000 | $2.00 | $2,000.00 | New | -12.5% | -41.1% |